Visit
The U.S. Food and Drug Administration (FDA) has authorized the marketing of the Fujirebio’s Lumipulse G β-Amyloid Ratio (1-42/1-40) in…
An exciting study published in Nature Genetics has doubled the number of genetic loci known to associate with Alzheimer’s disease,…
The Alzheimer’s Research UK Conference was held in Brighton, UK, on 1-2 March 2022. Leading experts discussed the key topics…
Atuzaginstat, a novel small-molecule bacterial protease lysine gingipain inhibitor, is currently under investigation as a first-in-class treatment to slow or…
